Tegaserod use in children: A single-center experience

Journal of Pediatric Gastroenterology and Nutrition

Volumn 46, Issue 1, 2008, Pages 54-58

  Liem, Olivia ^a,b   Mousa, Hayat M ^b   Benninga, Marc A ^a   Di Lorenzo, Carlo ^b  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

5 hydroxytryptamine; Abdominal pain; Constipation

Indexed keywords

TEGASEROD;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; BLOATING; CHILD; CONSTIPATION; DEFECATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; ENTERITIS; FECES INCONTINENCE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CONSTIPATION; DIARRHEA; DYSPEPSIA; GASTROINTESTINAL DISEASES; HUMANS; INDOLES; INFANT; INFLAMMATORY BOWEL DISEASES; RETROSPECTIVE STUDIES; SEROTONIN AGONISTS;

EID: 37549028843     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000304454.99799.42     Document Type: Article

References (21)

1. Molnar D, Taitz LS, Urwin OM, Loening-Baucke V. Chronic constipation in children. Gastroenterology 1993;105:1557-64.
2. van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol 2006;101:2401-9.
3. Baker SS, Liptak GS, Colletti RB, et al. Constipation in infants and children: evaluation and treatment. A medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1999;29:612-26.
4. van Ginkel R, Reitsma JB, Buller HA, et al. Childhood constipation: longitudinal follow-up beyond puberty. Gastroenterology 2003;125:357-63.
5. Coffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577-85.
6. Schikowski A, Thewissen M, Mathis C, et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002;14:221-7.
7. Degen L, Petrig C, Studer D, et al. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005;17:821-6.
8. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:191-6.
9. Muller-Lissner S, Kamm MA, Musoglu A, et al. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. Am J Gastroenterol 2006;101:2558-69.
10. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-6.
11. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877-88.
12. Carrier MN, Garinot O, Vitzling C. Stability and compatibility of tegaserod from crushed tablets mixed in beverages and foods. Am J Health Syst Pharm 2004;61:1135-42.
13. Camilleri M. Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment? Neurogastroenterol Motil 2007;19:77-84.
14. Brinker AD, Mackey AC, Prizont R. Tegaserod and ischemic colitis. N Engl J Med 2004;351:1361-4.
15. Walker AM, Bohn RL, Cali C, et al. Risk factors for colon ischemia. Am J Gastroenterol 2004;99:1333-7.
16. Shetzline MA, Cohard-Radice M, Joelsson B. Ischemic colitis, irritable bowel syndrome, and tegaserod - an alternative viewpoint. Pharmacotherapy 2005;25:1684-5.
17. Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998;97:204-10.
18. Drici MD, Ebert SN, Wang WX, et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 1999;34:82-8.
19. Busti AJ, Murillo JR Jr, Cryer B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004;24:526-31.
20. Ishida T, Kawashima S, Hirata K, et al. Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation 2001;103:1289-95.
21. Youssef NN, Langseder AL, Verga BJ, et al. Chronic childhood constipation is associated with impaired quality of life: a casecontrolled study. J Pediatr Gastroenterol Nutr 2005;41:56-60.